Drugs / Cisplatin
Cisplatin
Drug Licensed for medical use in 1978-1979; prescription-only in the U.S.Platinum-based antineoplastic·First approved·1978
- Registered trials
- 2356
- Ongoing
- 576/ 24%
- Completed
- 1124
- Indications
- 10
Approved indications
| Indication |
|---|
| Testicular cancer |
| Ovarian cancer |
| Cervical cancer |
| Bladder cancer |
| Head and neck cancer |
| Esophageal cancer |
| Lung cancer |
| Mesothelioma |
| Brain tumors |
| Neuroblastoma |
Clinical trial landscape
2356 registered studies reference this molecule or one of its brands. The split below shows how many are ongoing versus completed per phase.
| Phase | Total | Ongoing | Completed | Split |
|---|---|---|---|---|
| Phase 2 | 1085 | 258 | 521 | |
| Phase 3 | 566 | 165 | 254 | |
| Phase 1 | 346 | 54 | 217 | |
| Phase 1/2 | 177 | 33 | 78 | |
| Phase 2/3 | 71 | 36 | 15 | |
| Not applicable | 61 | 16 | 16 | |
| Unknown | 20 | 5 | 11 | |
| Phase 4 | 17 | 4 | 7 | |
| Early Phase 1 | 13 | 5 | 5 | |
| All phases | 2356 | 576 | 1124 |
Ongoing Completed Balance withdrawn, terminated, or status unreported.
Study records: ClinicalTrials.gov →
Mechanism of action
Binds and crosslinks DNA, interfering with DNA replication and mitosis and triggering apoptosis when damage cannot be repaired.
Recent developments
Headlines link to the original publisher. Sources limited to a reviewed list of journals, regulators, and medical press.